<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240746</url>
  </required_header>
  <id_info>
    <org_study_id>QIV04</org_study_id>
    <secondary_id>UTN: U1111-1114-3713</secondary_id>
    <nct_id>NCT01240746</nct_id>
  </id_info>
  <brief_title>Study of Quadrivalent Influenza Vaccine Among Children</brief_title>
  <official_title>Safety and Immunogenicity Among Children Administered Quadrivalent Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate a prototype quadrivalent influenza vaccine (QIV), the
      licensed 2010-2011 trivalent influenza vaccine (TIV) containing the primary B strain (B1),
      and the investigational TIV containing the alternate B (B2) strain in children.

      Primary Objective:

      To demonstrate non-inferiority of antibody responses to QIV compared with licensed 2010-2011
      TIV (containing the primary B strain) and investigational TIV (containing the alternate B
      strain) as assessed by geometric mean titer (GMT) ratios for each of the four virus strains
      separately among children aged 6 months to less than 9 years of age

      Secondary Objective:

      To demonstrate superiority of antibody responses to each B strain in QIV compared with
      antibody titers following vaccination with the TIV that does not contain the corresponding B
      strain, as assessed by GMT ratios and seroconversion rates.

      Observational Objective:

      To describe the safety profile of QIV among subjects 6 months to less than 9 years of age, as
      assessed by solicited injection site and systemic adverse events (AEs) collected for 7 days
      post-vaccination, unsolicited adverse events collected from 21 days post-vaccination, and
      adverse events of special interest and serious adverse events (SAEs) collected from Visit 1
      to Visit 2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will receive a single dose of their assigned vaccine during Visit 1. For those
      requiring two doses of influenza vaccine, as per Advisory Committee on Immunization Practices
      (ACIP) guidance, a second dose of the assigned vaccine will be administered at Visit 2. All
      participants will be followed up for safety (up to 6 months post final vaccination) and for
      immunogenicity up to Day 28 post-vaccination (Visit 2 or Visit 3, as appropriate).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥four-fold increase in post-vaccination</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil)</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants.</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With One Dose of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</measure>
    <time_frame>Day 28 post-vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
  </other_outcome>
  <other_outcome>
    <measure>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Two Doses of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</measure>
    <time_frame>Day 28 post final vaccination</time_frame>
    <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Aged 6 Months to &lt;36 Months Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines.</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions (Age 6-23 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability.
Grade 3: Tenderness: cries when injected limb is moved; Erythema and Swelling ≥ 50 mm; Fever: &gt;103.1°F; Vomiting: ≥6 episodes/24 hours; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals or most feeds/meals; Irritability: inconsolable.
Solicited Injection site reactions (Age 24 Months to &lt; 36 months): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3: Pain: Incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Aged 3 Years to &lt;9 Years Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</measure>
    <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
    <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Fever (Temperature); Headache, Malaise and Myalgia Grade 3 Pain: incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥ 102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity, respectively.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4363</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: Licensed 2010-2011 TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive the Licensed 2010-2011 Trivalent Influenza Vaccine containing the primary B strain.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Investigational TIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Investigational Trivalent Influenza Vaccine containing the alternate B strain</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Investigational QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the investigational Quadrivalent Influenza Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative</intervention_name>
    <description>0.25 mL (6 to 35 months) or 0.5 mL (3 to &lt;9 years), Intramuscular</description>
    <arm_group_label>Group 1: Licensed 2010-2011 TIV</arm_group_label>
    <other_name>Fluzone®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative</intervention_name>
    <description>0.25 mL (6 to 35 months) or 0.5 mL (3 to &lt;9 years), Intramuscular</description>
    <arm_group_label>Group 2: Investigational TIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Influenza Vaccine, No Preservative</intervention_name>
    <description>0.25 mL (6 to 35 months), or 0.5 mL(3 to &lt;9 years), Intramuscular</description>
    <arm_group_label>Group 3: Investigational QIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is 6 months to &lt; 9 years of age on the day of inclusion.

          -  Parent/guardian is willing and able to attend scheduled visits and to comply with the
             study procedures during the entire duration of the study.

          -  Subject is in reasonably good health as assessed by the Investigator.

          -  Informed consent is granted by the parent(s) or other legally acceptable
             representative; assent by subjects 7 to &lt; 9 years of age.

          -  For subjects 6 months to &lt; 24 months of age, born at full term of pregnancy (≥ 37
             weeks) and with a birth weight ≥ 2.5 kg (5.5 lbs).

        Exclusion Criteria:

          -  History of allergy to egg proteins or any constituents of the vaccine.

          -  History of serious adverse reaction to any influenza vaccine.

          -  Any vaccination scheduled between Visit 1 and Visit 2 (or Visit 1 and Visit 3 for
             those requiring two doses).

          -  Receipt of any vaccine in the 4 weeks preceding the first study vaccination.

          -  Participation in another interventional clinical trial investigating a vaccine, drug,
             medical device, or medical procedure in the 4 weeks preceding the first study
             vaccination or during the course of the study.

          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,
             contraindicating intramuscular vaccination.

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             subject if enrolled or could interfere with the evaluation of the vaccine.

          -  Personal history of Guillain-Barré syndrome.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within
             the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or
             equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Personal or immediate family history of congenital immune deficiency.

          -  Personal developmental delay, neurologic disorder, or seizure disorder.

          -  Any chronic illness that, in the opinion of the Investigator, is not well controlled
             and may interfere with trial conduct or completion, or with assessment of adverse
             events.

          -  Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.

          -  Receipt of blood or blood-derived products (including immunoglobulin therapy) in the
             past 3 months, which might interfere with assessment of the immune response.

          -  Employees of the Investigator or study center, with direct involvement in the proposed
             study or other studies under the direction of that Investigator or study center, as
             well as family members of the employees or the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Spring</city>
        <state>Colorado</state>
        <zip>80922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <zip>06877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkansas City</city>
        <state>Kansas</state>
        <zip>67005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crestview Hills</city>
        <state>Kentucky</state>
        <zip>41017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburg</city>
        <state>Pennsylvania</state>
        <zip>15220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scranton</city>
        <state>Pennsylvania</state>
        <zip>18510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnwell</city>
        <state>South Carolina</state>
        <zip>26812</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37664</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ft. Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77450</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orem</city>
        <state>Utah</state>
        <zip>84057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Williamsburg</city>
        <state>Virginia</state>
        <zip>23185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <results_reference>
    <citation>Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age. Pediatr Infect Dis J. 2014 Jun;33(6):630-6. doi: 10.1097/INF.0000000000000254.</citation>
    <PMID>24445833</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2010</study_first_submitted>
  <study_first_submitted_qc>November 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <results_first_submitted>July 3, 2013</results_first_submitted>
  <results_first_submitted_qc>December 12, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 14, 2014</results_first_posted>
  <disposition_first_submitted>March 29, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>March 29, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 2, 2012</disposition_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Quadrivalent Influenza Vaccine</keyword>
  <keyword>Trivalent Influenza Vaccine</keyword>
  <keyword>Influenza viruses</keyword>
  <keyword>Fluzone®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 11 November 2010 to 20 June 2011 in 69 clinical centers in the US</recruitment_details>
      <pre_assignment_details>A total of 4363 participants who met all the inclusion criteria and none of the exclusion criteria were enrolled, randomized and vaccinated in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Group 1 (2010-2011 Trivalent Influenza Vaccine)</title>
          <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen.</description>
        </group>
        <group group_id="P2">
          <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
        </group>
        <group group_id="P3">
          <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="736"/>
                <participants group_id="P2" count="725"/>
                <participants group_id="P3" count="2902"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="677"/>
                <participants group_id="P2" count="677"/>
                <participants group_id="P3" count="2659"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="243"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
          <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
        </group>
        <group group_id="B2">
          <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
        </group>
        <group group_id="B3">
          <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="736"/>
            <count group_id="B2" value="725"/>
            <count group_id="B3" value="2902"/>
            <count group_id="B4" value="4363"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="736"/>
                    <measurement group_id="B2" value="725"/>
                    <measurement group_id="B3" value="2902"/>
                    <measurement group_id="B4" value="4363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="29.0"/>
                    <measurement group_id="B2" value="49.6" spread="28.7"/>
                    <measurement group_id="B3" value="49.8" spread="29.7"/>
                    <measurement group_id="B4" value="49.8" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="367"/>
                    <measurement group_id="B2" value="359"/>
                    <measurement group_id="B3" value="1427"/>
                    <measurement group_id="B4" value="2153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="1475"/>
                    <measurement group_id="B4" value="2210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="736"/>
                    <measurement group_id="B2" value="725"/>
                    <measurement group_id="B3" value="2902"/>
                    <measurement group_id="B4" value="4363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Geometric mean titers (GMT) to influenza vaccine A antigens were determined in randomized and vaccinated participants, per-protocol population. The GMT data for antigen A/Victoria/210/2009 and A/California/07/2009 were pooled for participants vaccinated with either 2010-2011 TIV or the investigational TIV. Data presented in column for Group 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza A Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by hemagglutination inhibition (HAI) assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers (GMT) to influenza vaccine A antigens were determined in randomized and vaccinated participants, per-protocol population. The GMT data for antigen A/Victoria/210/2009 and A/California/07/2009 were pooled for participants vaccinated with either 2010-2011 TIV or the investigational TIV. Data presented in column for Group 1.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1461"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/California/07/2009 (A/H1N1) [N = 1461, 0, 2339]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1096" lower_limit="1008" upper_limit="1192"/>
                    <measurement group_id="O3" value="1124" lower_limit="1060" upper_limit="1192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Victoria/210/2009 (A/H3N2) [N = 1461, 0, 2339</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="828" lower_limit="774" upper_limit="887"/>
                    <measurement group_id="O3" value="822" lower_limit="783" upper_limit="862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥four-fold increase in post-vaccination</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroconversion with respect to influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre-vaccination HAI titer &lt;1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and ≥four-fold increase in post-vaccination</description>
          <population>Seroconversion with respect to influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (581, 0, 2336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="NA" lower_limit="0" upper_limit="0">B/Brisbane/60/2008 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="1677" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (0, 598, 2335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="383" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1543" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines With Corresponding B Strain in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine B antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (581, 0, 2238)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3" lower_limit="58.3" upper_limit="70.9"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="86.1" lower_limit="81.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (0, 598, 2338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="58.3" lower_limit="52.6" upper_limit="64.7"/>
                    <measurement group_id="O3" value="61.5" lower_limit="58.6" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine B antigens (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine B antigens (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (0, 599, 2338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O2" value="19.5" lower_limit="17.4" upper_limit="21.8"/>
                    <measurement group_id="O3" value="86.1" lower_limit="81.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (581, 0, 2338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3" lower_limit="14.8" upper_limit="17.9"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 antigen was not in the influenza vaccine administered to this group.</measurement>
                    <measurement group_id="O3" value="61.5" lower_limit="58.6" upper_limit="64.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil)</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroprotection against influenza vaccine antigens was determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil)</description>
          <population>Seroprotection against influenza vaccine antigens was determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 Pre-vaccination (581, 599, 2333)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="305" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1159" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 Post-vaccination (581, 597, 2337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573"/>
                    <measurement group_id="O2" value="585" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2305" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Pre-vaccination (579, 596, 2334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="248"/>
                    <measurement group_id="O2" value="241" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="946" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Post-vaccination (580, 599, 2334)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="575"/>
                    <measurement group_id="O2" value="593" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2326" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination 582, 599, 2337)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="79" lower_limit="25.0" upper_limit="33.7"/>
                    <measurement group_id="O3" value="261" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination (581, 599, 2338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418"/>
                    <measurement group_id="O2" value="202" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1838" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination (582, 598, 2336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="55" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="199" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination (581, 598, 2338)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="416" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1674" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroconversion with respect to vaccine antigens (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
          <population>Seroconversion with respect to vaccine antigens (cross-reactive antibody) were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (580, 597, 2331)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="535" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2135" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (578, 596, 2329)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477"/>
                    <measurement group_id="O2" value="512" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2050" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane (581, 599, 2336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="120" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1677" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida (581, 598, 2335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="383" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="1543" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 6 months to less than 36 months with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 6 months to less than 36 months with valid serology results for the particular antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (224, 245, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6" lower_limit="19.4" upper_limit="33.7"/>
                    <measurement group_id="O2" value="31.3" lower_limit="23.8" upper_limit="41.1"/>
                    <measurement group_id="O3" value="25.7" lower_limit="22.4" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (224, 243, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="797" lower_limit="664" upper_limit="957"/>
                    <measurement group_id="O2" value="645" lower_limit="530" upper_limit="784"/>
                    <measurement group_id="O3" value="747" lower_limit="680" upper_limit="821"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (224, 245, 945)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.52" lower_limit="7.90" upper_limit="11.5"/>
                    <measurement group_id="O2" value="10.1" lower_limit="8.26" upper_limit="12.3"/>
                    <measurement group_id="O3" value="9.19" lower_limit="8.42" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (224, 243, 944)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="558" lower_limit="483" upper_limit="646"/>
                    <measurement group_id="O2" value="583" lower_limit="507" upper_limit="671"/>
                    <measurement group_id="O3" value="526" lower_limit="492" upper_limit="562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Pre-vaccination (225, 245, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56" lower_limit="5.92" upper_limit="7.27"/>
                    <measurement group_id="O2" value="6.62" lower_limit="6.00" upper_limit="7.30"/>
                    <measurement group_id="O3" value="6.41" lower_limit="6.10" upper_limit="6.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Post-vaccination (225, 245, 948)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7" lower_limit="47.2" upper_limit="63.4"/>
                    <measurement group_id="O2" value="12.0" lower_limit="10.3" upper_limit="13.9"/>
                    <measurement group_id="O3" value="72.8" lower_limit="67.3" upper_limit="78.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Pre-vaccination (225, 245, 946)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" lower_limit="5.10" upper_limit="5.56"/>
                    <measurement group_id="O2" value="5.26" lower_limit="5.09" upper_limit="5.44"/>
                    <measurement group_id="O3" value="5.34" lower_limit="5.23" upper_limit="5.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Post-vaccination (225, 245, 948)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.56" lower_limit="7.68" upper_limit="9.54"/>
                    <measurement group_id="O2" value="32.9" lower_limit="28.7" upper_limit="37.6"/>
                    <measurement group_id="O3" value="36.2" lower_limit="33.7" upper_limit="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroconversion with respect to influenza vaccine B antigens (cross-reactive antibody) was determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigens.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Against Influenza B Strains After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines Without Corresponding B Strain in All Participants.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroconversion was defined as either a pre vaccination HAI titer &lt;1:10 and a post vaccination titer ≥1:40 or a pre-vaccination titer ≥1:10 and a four-fold increase in post-vaccination.</description>
          <population>Seroconversion with respect to influenza vaccine B antigens (cross-reactive antibody) was determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the B antigens.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="582"/>
                <count group_id="O2" value="599"/>
                <count group_id="O3" value="2339"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Brisbane/60/2008 (0, 599, 2336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">B/Florida/04/2006 antigen was not in the influenza vaccine administered to this group</measurement>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="1677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida/04/2006 (581, 0, 2335)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="NA">B/Brisbane/60/2008 antigen was not in the influenza vaccine administered to this group</measurement>
                    <measurement group_id="O3" value="1543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 6 months to less than 36 months with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 6 Months to Less Than 36 Months.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
          <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 6 months to less than 36 months with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="225"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="949"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Pre-vaccination (224, 245, 943)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Post-vaccination (223, 243, 941)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="925"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Pre-vaccination (224, 245, 945)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Post-vaccination (223, 243, 944)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="242"/>
                    <measurement group_id="O3" value="943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination (225, 245, 947)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination (225, 245, 948)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="716"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination (225, 245, 946)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination (225, 245, 948)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="135"/>
                    <measurement group_id="O3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 3 years to less than 9 years with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
          <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 3 years to less than 9 years with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="1390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Pre-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Post-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="348"/>
                    <measurement group_id="O3" value="1380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Pre-vaccination (355, 353, 1389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="212"/>
                    <measurement group_id="O3" value="842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Post-vaccination (356, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354"/>
                    <measurement group_id="O2" value="351"/>
                    <measurement group_id="O3" value="1383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination (356, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="1122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination (357, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination (356, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="281"/>
                    <measurement group_id="O3" value="1124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With One Dose of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With One Dose of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
          <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="141"/>
                <count group_id="O3" value="510"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Pre-vaccination (114, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Post-vaccination (114, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="139"/>
                    <measurement group_id="O3" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Pre-vaccination (112, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Post-vaccination (112, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="138"/>
                    <measurement group_id="O3" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination (114, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination (113, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination (114, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination (113, 141, 510)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Two Doses of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
        <time_frame>Day 28 post final vaccination</time_frame>
        <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Against Influenza Vaccine Antigens After Vaccination With Two Doses of Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in All Participants</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.
Seroprotection was defined as a pre-vaccination and post-vaccination titer ≥ 40 (l/dil).</description>
          <population>Seroprotection against influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants with valid serology results for the particular antigen.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="468"/>
                <count group_id="O2" value="458"/>
                <count group_id="O3" value="1829"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1 Pre-vaccination (467, 458, 1823)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229"/>
                    <measurement group_id="O2" value="216"/>
                    <measurement group_id="O3" value="870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H1N1 Post-vaccination (467, 456, 1827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="462"/>
                    <measurement group_id="O2" value="446"/>
                    <measurement group_id="O3" value="1807"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Pre-vaccination (467, 457, 1824)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="166"/>
                    <measurement group_id="O3" value="687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2 Post-vaccination (467, 455, 1824)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="465"/>
                    <measurement group_id="O2" value="455"/>
                    <measurement group_id="O3" value="1822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Pre-vaccination (468, 458, 1827)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane Post-vaccination (468, 458, 1828)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="1497"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Pre-vaccination (468, 457, 1826)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida Post-vaccination (468, 457, 1828)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                    <measurement group_id="O2" value="318"/>
                    <measurement group_id="O3" value="1324"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</title>
        <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
        <time_frame>Day 28 post-vaccination</time_frame>
        <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 3 years to less than 9 Years with valid serology results for the particular antigen.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Against Influenza Vaccine Antigens After Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines in Participants Aged 3 Years to Less Than 9 Years.</title>
          <description>Immunogenicity outcomes were assessed in serum samples by HAI assay. The lower limit of quantitation (LLOQ) was set at the lowest dilution used in the assay, 1/10. Titers below this level were reported as &lt;10.</description>
          <population>Geometric mean titers to influenza vaccine antigens were determined in randomized and vaccinated participants, per-protocol population. Data presented for participants aged 3 years to less than 9 Years with valid serology results for the particular antigen.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="357"/>
                <count group_id="O2" value="354"/>
                <count group_id="O3" value="1390"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, Pre-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5" lower_limit="43.9" upper_limit="65.2"/>
                    <measurement group_id="O2" value="54.4" lower_limit="44.4" upper_limit="66.8"/>
                    <measurement group_id="O3" value="54.9" lower_limit="49.6" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, Post-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1565" lower_limit="1355" upper_limit="1807"/>
                    <measurement group_id="O2" value="1348" lower_limit="1166" upper_limit="1559"/>
                    <measurement group_id="O3" value="1484" lower_limit="1380" upper_limit="1595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Pre-vaccination (355, 353, 1389)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.6" lower_limit="57.3" upper_limit="87.0"/>
                    <measurement group_id="O2" value="64.1" lower_limit="51.9" upper_limit="79.2"/>
                    <measurement group_id="O3" value="63.9" lower_limit="57.6" upper_limit="70.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, Post-vaccination (356, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="924" lower_limit="816" upper_limit="1046"/>
                    <measurement group_id="O2" value="1214" lower_limit="1078" upper_limit="1367"/>
                    <measurement group_id="O3" value="1112" lower_limit="1046" upper_limit="1183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Pre-vaccination (357, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.1" lower_limit="9.05" upper_limit="11.2"/>
                    <measurement group_id="O2" value="10.6" lower_limit="9.52" upper_limit="11.9"/>
                    <measurement group_id="O3" value="9.73" lower_limit="9.23" upper_limit="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane, Post-vaccination (356, 354, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.2" lower_limit="62.6" upper_limit="81.1"/>
                    <measurement group_id="O2" value="27.3" lower_limit="23.4" upper_limit="31.8"/>
                    <measurement group_id="O3" value="96.6" lower_limit="90.3" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Pre-vaccination (357, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" lower_limit="8.26" upper_limit="10.0"/>
                    <measurement group_id="O2" value="9.84" lower_limit="8.91" upper_limit="10.9"/>
                    <measurement group_id="O3" value="9.34" lower_limit="8.89" upper_limit="9.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Florida, Post-vaccination (356, 353, 1390)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.4" lower_limit="21.6" upper_limit="27.5"/>
                    <measurement group_id="O2" value="86.9" lower_limit="76.1" upper_limit="99.2"/>
                    <measurement group_id="O3" value="88.5" lower_limit="83.1" upper_limit="94.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Aged 6 Months to &lt;36 Months Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines.</title>
        <description>Solicited injection site reactions (Age 6-23 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability.
Grade 3: Tenderness: cries when injected limb is moved; Erythema and Swelling ≥ 50 mm; Fever: &gt;103.1°F; Vomiting: ≥6 episodes/24 hours; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals or most feeds/meals; Irritability: inconsolable.
Solicited Injection site reactions (Age 24 Months to &lt; 36 months): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3: Pain: Incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Safety profile were assessed in all randomized and vaccinated participants, safety population. Values presented for participants aged 6 months to &lt;36 months with available data for the relevant endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Aged 6 Months to &lt;36 Months Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines.</title>
          <description>Solicited injection site reactions (Age 6-23 Months): Tenderness, Erythema and Swelling. Solicited systemic reactions: Fever (Temperature), Vomiting, Abnormal crying, Drowsiness, Loss of appetite, and Irritability.
Grade 3: Tenderness: cries when injected limb is moved; Erythema and Swelling ≥ 50 mm; Fever: &gt;103.1°F; Vomiting: ≥6 episodes/24 hours; Abnormal crying: &gt;3 hours; Drowsiness: Sleeping most of the time; Loss of appetite: refuses ≥3 feeds/meals or most feeds/meals; Irritability: inconsolable.
Solicited Injection site reactions (Age 24 Months to &lt; 36 months): Pain, Erythema, and Swelling. Systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia.
Grade 3: Pain: Incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity.</description>
          <population>Safety profile were assessed in all randomized and vaccinated participants, safety population. Values presented for participants aged 6 months to &lt;36 months with available data for the relevant endpoint.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="310"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="1223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (130, 149, 521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="75" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="297" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (130, 149, 521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="5" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Tenderness (159, 145, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Tenderness (159, 145, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (289, 294, 1150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="98" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="429" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (289, 294, 1150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (289, 294, 1150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="51" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="248" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (289, 294, 1150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="2" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (288, 293, 1148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="38" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="164" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (288, 293, 1148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Vomiting (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Crying abnormal (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Drowsiness (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="46" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="3" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Appetite lost (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="48" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="197" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade Malaise (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="24" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="37" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="138" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (128, 148, 517)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="10" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Irritability (159, 144, 628)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Aged 3 Years to &lt;9 Years Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
        <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Fever (Temperature); Headache, Malaise and Myalgia Grade 3 Pain: incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥ 102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity, respectively.</description>
        <time_frame>Day 0 up to Day 7 post-vaccination</time_frame>
        <population>Safety profile were assessed in all randomized and vaccinated participants, safety population. Values presented for participants aged 3 years to &lt;9 years with available data for the relevant endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
            <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
          </group>
          <group group_id="O2">
            <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
          </group>
          <group group_id="O3">
            <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
            <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Aged 3 Years to &lt;9 Years Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With Fluzone® Quadrivalent Influenza Vaccine or Trivalent Influenza Vaccines</title>
          <description>Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Fever (Temperature); Headache, Malaise and Myalgia Grade 3 Pain: incapacitating, unable to perform usual activities; Redness and Swelling: ≥ 50 mm; Fever: ≥ 102.1°F; Headache, Malaise and Myalgia: Significant, prevents daily activity, respectively.</description>
          <population>Safety profile were assessed in all randomized and vaccinated participants, safety population. Values presented for participants aged 3 years to &lt;9 years with available data for the relevant endpoint.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="424"/>
                <count group_id="O2" value="413"/>
                <count group_id="O3" value="1669"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site Pain (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="254"/>
                    <measurement group_id="O3" value="1061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Pain (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Erythema (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Erythema (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site Swelling (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Injection site Swelling (410, 398, 1592)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever (409, 396, 1591)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fever (409, 396, 1591)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="97"/>
                    <measurement group_id="O3" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="133"/>
                    <measurement group_id="O3" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Malaise (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="153"/>
                    <measurement group_id="O3" value="615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia (411, 398, 1593)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected from Day 0 (post-vaccination) up to 6 months post-vaccination.</time_frame>
      <desc>Data are presented for participants with available safety data for the relevant endpoints.</desc>
      <group_list>
        <group group_id="E1">
          <title>Study Group 1 (Trivalent Influenza Vaccine)</title>
          <description>Participants received the Licensed 2010-2011 Trivalent Influenza Vaccine (TIV) containing the primary B strain influenza antigen</description>
        </group>
        <group group_id="E2">
          <title>Study Group 2 (Investigational Trivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Trivalent Influenza Vaccine (TIV) containing the alternate B strain influenza antigen</description>
        </group>
        <group group_id="E3">
          <title>Study Group 3 (Investigational Quadrivalent Influenza Vaccine)</title>
          <description>Participants received the Investigational Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="721"/>
                <counts group_id="E3" subjects_affected="41" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="225"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="721"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Mycoplasma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial vrus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial vrus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Staphylococcal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental exposure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="10" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Astrocytoma, low grade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="734"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="721"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Seizure anoxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Bronchial hrperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="734"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="721"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <default_vocab>MedDRA, version 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="333" subjects_at_risk="734"/>
                <counts group_id="E2" subjects_affected="329" subjects_at_risk="721"/>
                <counts group_id="E3" subjects_affected="1358" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="159"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="144"/>
                <counts group_id="E3" events="93" subjects_affected="93" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="51" subjects_affected="42" subjects_at_risk="734"/>
                <counts group_id="E2" events="48" subjects_affected="38" subjects_at_risk="721"/>
                <counts group_id="E3" events="150" subjects_affected="135" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="734"/>
                <counts group_id="E2" events="61" subjects_affected="55" subjects_at_risk="721"/>
                <counts group_id="E3" events="209" subjects_affected="193" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="333" subjects_affected="333" subjects_at_risk="540"/>
                <counts group_id="E2" events="329" subjects_affected="329" subjects_at_risk="547"/>
                <counts group_id="E3" events="1358" subjects_affected="1358" subjects_at_risk="2113"/>
              </event>
              <event>
                <sub_title>Injection site Swelling</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="162" subjects_affected="161" subjects_at_risk="734"/>
                <counts group_id="E2" events="154" subjects_affected="154" subjects_at_risk="692"/>
                <counts group_id="E3" events="643" subjects_affected="643" subjects_at_risk="2742"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="180" subjects_affected="180" subjects_at_risk="539"/>
                <counts group_id="E2" events="181" subjects_affected="181" subjects_at_risk="546"/>
                <counts group_id="E3" events="705" subjects_affected="705" subjects_at_risk="2110"/>
              </event>
              <event>
                <sub_title>Injection site tenderness</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="159"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="145"/>
                <counts group_id="E3" events="340" subjects_affected="340" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="246" subjects_affected="246" subjects_at_risk="699"/>
                <counts group_id="E2" events="238" subjects_affected="238" subjects_at_risk="692"/>
                <counts group_id="E3" events="972" subjects_affected="972" subjects_at_risk="2742"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="75" subjects_affected="75" subjects_at_risk="695"/>
                <counts group_id="E2" events="68" subjects_affected="68" subjects_at_risk="689"/>
                <counts group_id="E3" events="276" subjects_affected="276" subjects_at_risk="2739"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="49" subjects_affected="44" subjects_at_risk="734"/>
                <counts group_id="E2" events="75" subjects_affected="65" subjects_at_risk="721"/>
                <counts group_id="E3" events="213" subjects_affected="188" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="51" subjects_affected="43" subjects_at_risk="734"/>
                <counts group_id="E2" events="50" subjects_affected="47" subjects_at_risk="721"/>
                <counts group_id="E3" events="203" subjects_affected="184" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite lost</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="159"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="144"/>
                <counts group_id="E3" events="203" subjects_affected="203" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="174" subjects_affected="174" subjects_at_risk="539"/>
                <counts group_id="E2" events="190" subjects_affected="190" subjects_at_risk="546"/>
                <counts group_id="E3" events="753" subjects_affected="753" subjects_at_risk="2110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="99" subjects_affected="99" subjects_at_risk="539"/>
                <counts group_id="E2" events="115" subjects_affected="115" subjects_at_risk="546"/>
                <counts group_id="E3" events="414" subjects_affected="414" subjects_at_risk="2110"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="159"/>
                <counts group_id="E2" events="46" subjects_affected="46" subjects_at_risk="144"/>
                <counts group_id="E3" events="237" subjects_affected="237" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying abnormal</sub_title>
                <counts group_id="E1" events="58" subjects_affected="58" subjects_at_risk="159"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="144"/>
                <counts group_id="E3" events="259" subjects_affected="259" subjects_at_risk="628"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="84" subjects_affected="84" subjects_at_risk="159"/>
                <counts group_id="E2" events="77" subjects_affected="77" subjects_at_risk="144"/>
                <counts group_id="E3" events="339" subjects_affected="339" subjects_at_risk="628"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="107" subjects_affected="95" subjects_at_risk="734"/>
                <counts group_id="E2" events="100" subjects_affected="89" subjects_at_risk="721"/>
                <counts group_id="E3" events="381" subjects_affected="341" subjects_at_risk="2892"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="38" subjects_affected="37" subjects_at_risk="734"/>
                <counts group_id="E2" events="39" subjects_affected="34" subjects_at_risk="721"/>
                <counts group_id="E3" events="189" subjects_affected="167" subjects_at_risk="2892"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

